Importantly, such a binding between Grb2 SH2 domain and BCR tyrosine 177 is required for induction of CML-like myeloproliferative disease driven by BCR-ABL in mouse model35. This evidence concerns the gene GRB2 and chronic myelogenous leukemia, BCR-ABL1 positive.